Posted by Michael Wonder on 14 Apr 2020
Insurers, drug makers, and patient advocates blast two Trump proposals to drive down drug prices
10 April 2020 - The Trump administration has proposed modest steps this year to promote biosimilar and generic medications, but each proposal has been met with staunch opposition from nearly all corners of the health care industry.
The proposals are small and wonky: under one, bonuses for insurers would be partially determined based on how often they encourage patients to use generic drugs; under another, insurers would be able to push patients toward lower-cost medicines by creating a new “tier” of medicines in their plan designs.
